The Xarelto from Bayer AG - once-daily dose, broad cardiovascular use

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 14:21. Details in the imprint.

The Xarelto tablet from Bayer AG sits light and small between finger and thumb, a smooth pill that promises to keep dangerous clots at bay with a single daily dose. In clinics and home medicine cabinets alike, it has become a quiet staple of modern cardiovascular therapy.

What Xarelto is used for

Xarelto is a direct oral anticoagulant based on the active substance rivaroxaban and is approved to treat and prevent blood clots across several indications, including deep vein thrombosis, pulmonary embolism and prevention of stroke in non-valvular atrial fibrillation.The official Xarelto patient site details these indications.
In Europe and many international markets, doctors prescribe Xarelto as an alternative to traditional vitamin K antagonists, reducing the need for frequent blood tests and dietary restrictions for suitable patients.The European Medicines Agency product information confirms its approved uses.

How the once-daily dosing works

Depending on the indication, Xarelto is taken once or twice daily with different tablet strengths, but a once-daily 20 mg dose is typical for stroke prevention in atrial fibrillation, taken with food to optimize absorption.The prescribing information from Bayer outlines the recommended regimens
For many patients, that single tablet rhythm quickly becomes part of the morning or evening routine, adding a tactile sense of control over an invisible risk.

What patients and doctors notice

In a typical cardiology ward, chief physician Dr. Martina Keller will often run her finger down a medication chart and pause at Xarelto, checking kidney function and bleeding risk before signing off on the dose.
Patients usually feel no direct effect from the drug itself, but they do notice the absence of repeated blood draws that accompanied older therapies and often describe the regimen as more practical and tidy.

Risk profile and monitoring

Like all anticoagulants, Xarelto increases the risk of bleeding, including gastrointestinal and intracranial hemorrhage, and prescribers are advised to weigh this carefully against the benefits of stroke prevention.
Unlike vitamin K antagonists, routine coagulation monitoring is generally not required, which simplifies handling but also means doctors must rely on clinical judgment and renal function tests when adjusting therapy.

Market role in Bayer's portfolio

For Bayer, Xarelto has been a flagship cardiovascular product for years and is co-marketed with partner Janssen in several regions, contributing materially to prescription revenue and brand recognition in the anticoagulant class.
Management, led by CEO Bill Anderson, regularly highlights the importance of established therapies like Xarelto alongside newer pipeline assets when presenting the pharma strategy to investors.

Stock and company context

All told, Xarelto illustrates how a single, small tablet can become a strategic pillar of a global pharmaceutical group, connecting everyday dosing routines with long-term earnings streams. Bayer AG shares (ISIN DE000BAY0017) trade in Germany on Xetra in euros and remain closely watched by health care-focused investors.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.